Corrigendum to “Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway” [EBioMedicine 38 (2018) 25–36]

The authors regret that the representative pictures in Figure 4A/C, 5E/G were incorrectly presented in the published version of this article. Due to similar research objectives (platinum chemotherapy induced resistance and epithelial–mesenchymal transition), grouping and naming methods with another study being conducted simultaneously by the researchers (Oncotarget. 2017 Oct 10; 8(61):103815–103827), unintentional image duplication errors occurred in retrieving representative images during figure assembly. The authors actively identified the errors, rechecked all raw data and original groupings, and made corrections. The representative pictures of Fig. 4A (0 h), Fig. 4C (Control, OXA), Fig. 5E (48 h) and Fig. 5G (OXA, OXA + SAL) were wrongly presented. To better present the experimental trend, the representative images of the same batch were replaced simultaneously in the corrected Fig. 4A (48 h) and Fig. 5E (0 h). The rechecked statistical results (Figs. 4B and 5F) were consistent with the previous experimental conclusion. And the misspelled “E-cadherin” in Fig. 4E was also corrected. The corrected Figs. 4 and 5 were presented below.

Fig. 4.

Sal inhibited migration and invasion and reversed the changes in EMT biomarkers. (A–B) Cell migration was measured after treatment with various drugs for 48 h. (C–D) Representative images of Transwell cell invasion assays were obtained at 200× magnification. (E–F) Double immunofluorescence staining for E-cadherin and vimentin after treated with Sal. (G–H) The expression levels of HIF-1α in tumor tissues of subcutaneously transplanted tumor mice. Error bars represent the standard deviation of experiments performed in triplicate (∗P < 0.05, ∗∗∗P < 0.01).

Fig. 5.

Sal inhibits HIF-1α signaling pathway. (A) Protein expression level of HIF-1α after treatment with the protein synthesis inhibitor CHX in PLC/PRF/5 cells. (B) Protein expression level of HIF-1α after treatment with the proteasome inhibitor MG132 in PLC/PRF/5 cells. (C) Protein expression level after incubation with the proteasome inhibitor in PLC/PRF/5 cells. (D) Protein expression level of HIF-1α after overexpression of mutational HIF-1α in PLC/PRF/5 cells. (E–F) Cell migration was measured after overexpression of mutational HIF-1α in PLC/PRF/5 cells. (G–H) Representative images of Transwell cell invasion assays after overexpression of mutational HIF-1α in PLC/PRF/5 cells. (I) The relative IC₅₀ values for OXA of PLC/PRF/5 after overexpression of mutational HIF-1α. Error bars represent the standard deviation of experiments performed in triplicate (∗P < 0.05, ∗∗P < 0.01).

These corrections didn't change the description, interpretation, or the original conclusions of the article. The authors sincerely apologize for any inconvenience caused by these unintentional errors.

The corrected Fig. 4.

The corrected Fig. 5.